on Zomedica Corp. (NASDAQ:ZOM)
Zomedica Enhances Equine Insulin Testing with TRUFORMA Platform Update
Zomedica Corp., a veterinary health company, has launched an enhanced equine insulin assay for its TRUFORMA diagnostic platform. This update introduces an automatic sample dilution feature, increasing the test's dynamic range. Veterinary professionals can now measure higher insulin levels more efficiently.
The automatic dilution feature eliminates the need for manual protocols, ensuring consistent results while saving time. TRUFORMA's increased dynamic range further cements its position as a leading equine insulin testing solution. With laminitis risk linked to insulin dysregulation, this advancement aids faster decision-making in veterinary care.
The TRUFORMA Insulin assay for equine plasma is available for order. For more details, visit Zomedica's website.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Zomedica Corp. news